Breaking News Instant updates and real-time market news.

KERX

Acquired by AKBA 12/18

$2.97

-0.03 (-1.00%)

, AKBA

Akebia

$8.05

-0.07 (-0.86%)

08:58
11/30/18
11/30
08:58
11/30/18
08:58

Keryx announces Glass Lewis recommendation for Akebia merger

Keryx (KERX) announced that independent proxy advisory firm Glass Lewis recommends Keryx stockholders vote "FOR" the proposals relating to the proposed merger with Akebia (AKBA) at the special meeting of Keryx stockholders to be held on December 11. In recommending that Keryx stockholders vote "FOR" the merger and the related proposals, Glass Lewis recognized in its report that "the fundamental underpinnings of the proposed arrangement are both straightforward and sound" and that there is "a compelling case to combine the two firms." The Keryx board unanimously recommends that Keryx stockholders vote "FOR" the proposals relating to the proposed merger. Additionally, Keryx's largest stockholder, The Baupost Group, has entered into a voting agreement in support of the transaction.

KERX

Acquired by AKBA 12/18

$2.97

-0.03 (-1.00%)

AKBA

Akebia

$8.05

-0.07 (-0.86%)

  • 03

    Dec

  • 11

    Dec

  • 11

    Dec

KERX Acquired by AKBA 12/18
$2.97

-0.03 (-1.00%)

11/12/18
11/12/18
DOWNGRADE

Market Perform
Raymond James downgrades Keryx to Market Perform ahead of Akebia deal closing
As previously reported, Raymond James analyst Reni Benjamin downgraded Keryx (KERX) to Market Perform from Outperform as he sees shares trading in-line with the market until the merger with Akebia (AKBA) is complete. The potential merger with Akebia is likely to go through by year-end, Benjamin contends. The merged company is likely to become "a fully-integrated renal powerhouse," the analyst added.
11/12/18
RAJA
11/12/18
DOWNGRADE
RAJA
Market Perform
Keryx downgraded to Market Perform from Outperform at Raymond James
08/23/18
HCWC
08/23/18
NO CHANGE
HCWC
Keryx, Akebia merger remains on track, says H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert believes the merger between Keryx Biopharmaceuticals (KERX) and Akebia Therapeutics (AKBA) remains on track. According to the Federal Trade Commission website, the status of the merger application now shows "granted," Kolbert tells investors in a research note. The analyst says that while he did not expect FTC clearance to be an issue, "it's good to see it granted." He keeps a Buy rating on Keryx with a $9 price target.
07/12/18
PIPR
07/12/18
NO CHANGE
Target $22
PIPR
Overweight
Piper incrementally positive on Akebia shares, ups target to $22
Piper Jaffray analyst Christopher Raymond is incrementally positive on shares of Akebia Therapeutics after new nephrologist survey data indicated that Auryxia "has not just turned a corner, but is really on quite a roll, both in terms of the drug's perception and its market share dynamics." With the stock down 4% since before last month's merger announcement with Keryx (KERX), Raymond sees a "significant opportunity" to own Akebia before the drug's near-term share gains and the "real potential of a nephrology powerhouse with both Auryxia and vadadustat, become more apparent." He raised his price target for the shares to $22 from $20 and keeps an Overweight rating on the name.
AKBA Akebia
$8.05

-0.07 (-0.86%)

10/22/18
MZHO
10/22/18
NO CHANGE
Target $17
MZHO
Buy
Akebia 'significantly undervalued' ahead of catalysts, says Mizuho
Mizuho analyst Difei Yang views Akebia Therapeutics as "significantly undervalued" ahead of catalysts expected in 2019 including data readouts from vadadustat and launch metrics from Auryxia. The stock is one to pay attention to in 2019 following poor performance in 2018 "despite making progress in multiple pivotal trials," Yang tells investors in a research note. She lowered her price target for the shares to $17 from $21 and keeps a Buy rating on Akebia.
09/07/18
MSCO
09/07/18
INITIATION
Target $9
MSCO
Equal Weight
Akebia resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Akebia (AKBA) with an Equal Weight rating and $9 price target, stating that value is primarily driven by the potential of vadadustat as a treatment for anemia associated with chronic kidney disease. Vadadustat is a year behind FibroGen's (FGEN) competing HIF-inhibitor roxadustat and that lead could be an advantage if the data for the two drugs is not sufficiently differentiated, said Lebowitz.

TODAY'S FREE FLY STORIES

AMRN

Amarin

$22.66

1.17 (5.44%)

10:05
11/15/19
11/15
10:05
11/15/19
10:05
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

10:05
11/15/19
11/15
10:05
11/15/19
10:05
General news
The industrial production report sharply undershot estimates »

The industrial production…

10:02
11/15/19
11/15
10:02
11/15/19
10:02
General news
Business Inventories data reported »

September Business…

NCNA

NuCana

$5.59

(0.00%)

10:02
11/15/19
11/15
10:02
11/15/19
10:02
Recommendations
NuCana analyst commentary  »

NuCana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KZR

Kezar Life Sciences

$2.59

(0.00%)

10:02
11/15/19
11/15
10:02
11/15/19
10:02
Conference/Events
Kezar Life Sciences management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

FSM

Fortuna Silver Mines

$3.01

-0.19 (-5.94%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Fortuna Silver Mines falls -6.3% »

Fortuna Silver Mines is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

LN

Line Corp.

$46.46

-4.13 (-8.16%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Line Corp. falls -8.2% »

Line Corp. is down -8.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CANG

Cango

$5.83

-1.01 (-14.77%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Cango falls -10.4% »

Cango is down -10.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCH

Banco de Chile

$23.88

2.49 (11.64%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Banco de Chile rises 11.5% »

Banco de Chile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCB

Itau Corpbanca

$7.51

(0.00%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Itau Corpbanca rises 14.2% »

Itau Corpbanca is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$9.80

2.31 (30.84%)

10:00
11/15/19
11/15
10:00
11/15/19
10:00
Hot Stocks
Farfetch rises 31.1% »

Farfetch is up 31.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRP

Kimbell Royalty Partners

$13.99

(0.00%)

09:58
11/15/19
11/15
09:58
11/15/19
09:58
Conference/Events
Kimbell Royalty Partners management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

BANC

Banc of California

$14.75

(0.00%)

, FCBP

First Choice Bank

$22.50

(0.00%)

09:57
11/15/19
11/15
09:57
11/15/19
09:57
Hot Stocks
Banc of California names Lynn Hopkins as CFO after John Bogler resigns »

Banc of California…

BANC

Banc of California

$14.75

(0.00%)

FCBP

First Choice Bank

$22.50

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$61.35

4.46 (7.84%)

, PCG

PG&E

$6.92

0.22 (3.28%)

09:55
11/15/19
11/15
09:55
11/15/19
09:55
Options
Early notable gainers among liquid option names on November 15th »

Notable gainers among…

AMAT

Applied Materials

$61.35

4.46 (7.84%)

PCG

PG&E

$6.92

0.22 (3.28%)

DHR

Danaher

$141.30

5.14 (3.78%)

LRCX

Lam Research

$281.95

7 (2.55%)

OXY

Occidental Petroleum

$39.06

1.3 (3.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 09

    Dec

  • 09

    Dec

  • 07

    Jan

EA

Electronic Arts

$99.12

1.58 (1.62%)

09:51
11/15/19
11/15
09:51
11/15/19
09:51
Recommendations
Electronic Arts analyst commentary  »

EA's new Star Wars…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

09:50
11/15/19
11/15
09:50
11/15/19
09:50
General news
FX Action: The dollar »

FX Action: The dollar…

09:50
11/15/19
11/15
09:50
11/15/19
09:50
General news
The October trade price report »

The October trade price…

GDDY

GoDaddy

$68.00

0.22 (0.32%)

09:48
11/15/19
11/15
09:48
11/15/19
09:48
Periodicals
GoDaddy's new investors include 'constructive activist,' Dealreporter says »

"Constructive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 09

    Dec

BCH

Banco de Chile

$21.39

(0.00%)

09:47
11/15/19
11/15
09:47
11/15/19
09:47
Hot Stocks
Banco de Chile rises 10.4% »

Banco de Chile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSAC

Santander Chile

$24.53

2.37 (10.69%)

09:47
11/15/19
11/15
09:47
11/15/19
09:47
Hot Stocks
Santander Chile rises 11.2% »

Santander Chile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$9.97

2.48 (33.11%)

09:47
11/15/19
11/15
09:47
11/15/19
09:47
Hot Stocks
Farfetch rises 33.2% »

Farfetch is up 33.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
11/15/19
11/15
09:45
11/15/19
09:45
General news
U.S. business inventory preview: »

U.S. business inventory…

09:45
11/15/19
11/15
09:45
11/15/19
09:45
General news
Business Inventories to be reported at 10:00 »

September Business…

EWW

iShares MSCI Mexico

$44.07

(0.00%)

, RH

RH

$175.19

(0.00%)

09:40
11/15/19
11/15
09:40
11/15/19
09:40
Options
Unusually active option classes on open November 15th »

Unusual total active…

EWW

iShares MSCI Mexico

$44.07

(0.00%)

RH

RH

$175.19

(0.00%)

PDD

Pinduoduo

$41.29

(0.00%)

ORCL

Oracle

$56.10

(0.00%)

JCP

J.C. Penney

$1.10

(0.00%)

AMRN

Amarin

$21.49

(0.00%)

CSCO

Cisco

$44.92

(0.00%)

GRUB

GrubHub

$38.52

(0.00%)

QCOM

Qualcomm

$90.48

(0.00%)

BA

Boeing

$367.30

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

  • 10

    Dec

  • 28

    Dec

  • 12

    Feb

09:40
11/15/19
11/15
09:40
11/15/19
09:40
General news
Treasury Action: Wall Street remains buoyed by trade hopes »

Treasury Action: Wall…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.